{
    "clinical_study": {
        "@rank": "45368", 
        "arm_group": [
            {
                "arm_group_label": "AP301", 
                "arm_group_type": "Experimental", 
                "description": "Treatment group"
            }, 
            {
                "arm_group_label": "Saline solution", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of orally inhaled AP-301 on primary\n      graft dysfunction after lung transplantation."
        }, 
        "brief_title": "Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "PGD Primary Graft Dysfunction", 
        "condition_browse": {
            "mesh_term": "Primary Graft Dysfunction"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Being a male or female recipient on the AKH`s waiting list for primary single or\n             double LuTX\n\n          -  PGD score \u2265 1 within 72 hours after LuTX\n\n          -  Informed consent is available\n\n        Exclusion Criteria:\n\n          -  History of clinically relevant allergies or idiosyncrasies to AP301 or any other\n             inactive ingredient(s) of the investigational product\n\n          -  Postoperative ECMO support\n\n          -  Paediatric /adolescent recipients (< 18 years)\n\n          -  Lobar transplantation\n\n          -  Retransplantation\n\n          -  Combined solid organ transplants\n\n          -  Participation in other drug trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095626", 
            "org_study_id": "AP-301-III-001", 
            "secondary_id": "2013-000716-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "AP301", 
                "description": "orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days", 
                "intervention_name": "AP-301", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline solution", 
                "description": "placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days", 
                "intervention_name": "saline solution", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "contact": {
                "email": "clemens.aigner@meduniwien.ac.at", 
                "last_name": "Clemens Aigner, Ass.Prof.Priv.-Doz. Dr.", 
                "phone": "0043140400", 
                "phone_ext": "5620"
            }, 
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Division of Thoracic Surgery MedUni Vienna"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Study to Investigate the Clinical Effect of Orally Inhaled AP301 on Treatment of Primary Graft Dysfunction (PGD) in Mechanically Ventilated Patients After Primary Lung Transplantation", 
        "overall_contact": {
            "email": "b.fischer@apeptico.com", 
            "last_name": "Bernhard Fischer, Doz", 
            "phone": "0043664143", 
            "phone_ext": "2919"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Vienna", 
            "last_name": "Walter Klepetko, Univ.Prof.Dr.med.univ.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Ethikkommission", 
                "Austria: Agency for Health and Food Safety"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The changes of the P/F ratio from T0 (time of PGD diagnosis) to day 7 of the treatment or to extubation of the patient", 
            "measure": "P/F ratio", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095626"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measurement of extravascular lung water", 
            "measure": "EVLW", 
            "safety_issue": "No", 
            "time_frame": "7 days or until extubation"
        }, 
        "source": "Apeptico Forschung und Entwicklung GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Apeptico Forschung und Entwicklung GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}